Aprio Wealth Management LLC Makes New $248,000 Investment in GSK PLC Sponsored ADR $GSK

Key Points

• Aprio Wealth Management LLC purchased 6,397 shares of GSK PLC Sponsored ADR, valued at approximately $248,000, marking a new position in the pharmaceutical company during Q1.
• GSK recently reported earnings per share (EPS) of $1.23 for the last quarter, surpassing analyst expectations and showing a 1.3% increase in revenue compared to the previous year.
• The company declared a quarterly dividend of $0.4206, representing a 4.3% dividend yield, while its payout ratio currently stands at 77.78%.

Aprio Wealth Management LLC purchased a new position in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 6,397 shares of the pharmaceutical company's stock, valued at approximately $248,000.

Several other large investors have also recently modified their holdings of the stock. GW Henssler & Associates Ltd. raised its position in shares of GSK by 6.3% in the 1st quarter. GW Henssler & Associates Ltd. now owns 17,446 shares of the pharmaceutical company's stock worth $713,000 after purchasing an additional 1,039 shares during the last quarter. Royal Bank of Canada raised its position in shares of GSK by 5.7% in the 1st quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company's stock worth $293,692,000 after purchasing an additional 411,869 shares during the last quarter. MAI Capital Management raised its position in shares of GSK by 2.3% in the 1st quarter. MAI Capital Management now owns 26,275 shares of the pharmaceutical company's stock worth $1,018,000 after purchasing an additional 592 shares during the last quarter. Calton & Associates Inc. raised its position in shares of GSK by 17.9% in the 1st quarter. Calton & Associates Inc. now owns 7,261 shares of the pharmaceutical company's stock worth $281,000 after purchasing an additional 1,102 shares during the last quarter. Finally, Baird Financial Group Inc. increased its holdings in GSK by 5.0% in the 1st quarter. Baird Financial Group Inc. now owns 24,790 shares of the pharmaceutical company's stock worth $960,000 after buying an additional 1,179 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on GSK shares. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, GSK currently has a consensus rating of "Reduce" and an average price target of $37.38.

GSK Stock Performance

Shares of GSK stock traded down $0.31 during trading hours on Wednesday, reaching $40.48. 1,102,732 shares of the stock traded hands, compared to its average volume of 5,076,357. The company has a 50 day moving average price of $38.59 and a 200 day moving average price of $38.40. The firm has a market capitalization of $82.44 billion, a price-to-earnings ratio of 18.75, a P/E/G ratio of 2.00 and a beta of 0.53. GSK PLC Sponsored ADR has a one year low of $31.72 and a one year high of $44.03. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business's quarterly revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 dividend on an annualized basis and a yield of 4.2%. GSK's dividend payout ratio (DPR) is presently 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.